Sector | Healthcare | Compare with Sector peers |
Industry | Pharmaceuticals & Drugs | Compare with Industry peers |
Website | http://www.gtbl.in | |
Market Cap | 2,941.34 Cr. | |
Enterprise Value(EV) | 2,936.66 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 7.57 | Trailing Twelve Months Ending 2023-12 |
Price-Earning Ratio (PE) | 53.51 | Trailing Twelve Months Ending 2023-12 |
Industry PE | 42.15 | Trailing Twelve Months Ending 2023-12 |
Book Value / Share | 26.29 | Trailing Twelve Months Ending 2023-12 |
Price to Book Value | 15.40 | Calculated using Price: 404.90 |
Dividend Yield | 0.27 | Period Ending 2023-03 |
No. of Shares Subscribed | 7.26 Cr. | 72,643,510 Shares |
FaceValue | 1 | |
About Gujarat Themis Biosyn Ltd. | ||
Gujarat Themis Biosyn Ltd, established in 1981, is a biotech and synthetic product manufacturing company, having plants at Vapi, Hyderabad, with group turnover of over $ 40 million. It has EDMFs, available and WHO approved plants.The company has world-wide exports to satisfied customers, having customised facility for all products.The company’s principal activity is to manufacture and distributes pharmaceuticals bulk drugs called rifampicin produced by fermentation process. The company's products include preparations of active pharmaceutical ingredient rifampicin and lovastatin. The company exports its products to Europe and the United States. |
1 Day |
|
-0.50% |
1 Week |
|
+0.05% |
1 Month |
|
+6.55% |
3 Month |
|
+19.60% |
6 Month |
|
+87.32% |
1 Year |
|
+171.71% |
2 Year |
|
+334.40% |
5 Year |
|
+5012.37% |
10 Year |
|
+20988.54% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 0 | 302.71 | 72.63 | 38.06 | 41.85 | 77.99 | 53.82 | 50.35 | 45.92 | |
Return on Capital Employed (%) | 113.74 | 80.38 | 54.67 | 42.22 | 44.88 | 85.96 | 67.89 | 67.91 | 61.53 | |
Return on Assets (%) | 29.88 | 31.5 | 24.25 | 18.45 | 24.07 | 45.62 | 35.65 | 37.08 | 35.81 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | -1 | 4 | 8 | 12 | 19 | 42 | 70 | 103 | 149 | 178 | |
Non Curr. Liab. | 6 | 2 | 1 | 0 | 1 | 5 | 2 | 2 | 2 | 3 | |
Curr. Liab. | 10 | 9 | 12 | 8 | 13 | 24 | 26 | 32 | 36 | 16 | |
Minority Int. | |||||||||||
Equity & Liab. | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 187 | 197 | |
Non Curr. Assets | 11 | 11 | 13 | 13 | 25 | 35 | 25 | 44 | 105 | 149 | |
Curr. Assets | 3 | 3 | 8 | 8 | 8 | 36 | 73 | 93 | 81 | 48 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 15 | 15 | 21 | 20 | 33 | 71 | 98 | 137 | 187 | 197 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
Net Sales | 31 | 33 | 36 | 39 | 41 | 85 | 91 | 115 | 149 | 156 | |
Other Income | 0 | 0 | 0 | 0 | 2 | 2 | 3 | 4 | 6 | 4 | |
Total Income | 32 | 33 | 36 | 39 | 43 | 87 | 94 | 119 | 155 | 161 | |
Total Expenditure | -25 | -27 | -30 | -33 | -34 | -53 | -50 | -57 | -75 | -83 | |
PBIDT | 6 | 6 | 6 | 6 | 10 | 34 | 44 | 62 | 80 | 77 | |
Interest | 0 | 0 | 0 | 0 | 0 | -1 | -1 | -1 | 0 | 0 | |
Depreciation | -1 | -1 | -1 | -1 | -1 | -1 | -2 | -2 | -3 | -3 | |
Taxation | -1 | -1 | -2 | -8 | -11 | -15 | -20 | -19 | |||
Exceptional Items | |||||||||||
PAT | 5 | 5 | 4 | 4 | 6 | 24 | 30 | 44 | 58 | 55 | |
Adjusted EPS | 1 | 1 | 1 | 1 | 1 | 3 | 4 | 6 | 8 | 8 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 4 | 3 | 4 | 3 | 6 | 1 | 1 | 11 | 40 | 40 | |
Cash Fr. Inv. | 0 | 0 | -1 | -3 | -1 | -6 | -3 | -2 | -30 | -20 | |
Cash Fr. Finan. | -3 | -3 | -3 | 0 | -4 | 5 | 2 | -5 | -14 | -13 | |
Net Change | 1 | -1 | 0 | 0 | 1 | 0 | 0 | 3 | -4 | 6 | |
Cash & Cash Eqvt | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 0 | 6 |
Fri, 03 May 2024
Corporate Action-Board to consider Dividend Please refer our intimation on the captioned subject |
Fri, 03 May 2024
Corporate Action-Board to consider Bonus Issue Please find our intimation on the captioned subject |
Fri, 03 May 2024
Board Meeting Intimation for 1) Approval Of Results For The FY 23-242) Recommendation Of Dividend 3) Bonus Issue GUJARAT THEMIS BIOSYN LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/05/2024 inter alia to consider and approve 1) To consider and approve the Audited Financial Results for the Quarter/Year ended on 31st March 2024.2) To consider recommending Dividend if any on the equity shares of the Company for the financial year 2023-24.3) To consider proposal for the Issue of Bonus Shares to the equity shareholders of the Company |
Fri, 03 May 2024 |
High Delivery Percentage |
Closing Below Previous Low |
Close Within 52 Week High Zone |
High Increase in 1 Month |
High Increase in 3 Months |